These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 9628869)

  • 41. Crystal structure of a mutant mineralocorticoid receptor responsible for hypertension.
    Fagart J; Huyet J; Pinon GM; Rochel M; Mayer C; Rafestin-Oblin ME
    Nat Struct Mol Biol; 2005 Jun; 12(6):554-5. PubMed ID: 15908963
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Analysis of the hormone-binding domain of steroid receptors using chimeras generated by homologous recombination.
    Martinez ED; Pattabiraman N; Danielsen M
    Exp Cell Res; 2005 Aug; 308(2):320-33. PubMed ID: 15936754
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Role of the A/B region of the human mineralocorticoid receptor in aldosterone response selectivity.
    Jausons-Loffreda N; Chabret C; Pons M
    Biochem Biophys Res Commun; 1994 Dec; 205(3):1610-6. PubMed ID: 7811243
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Structural determinants of activation of the mineralocorticoid receptor: an evolutionary perspective.
    Fuller PJ; Yao YZ; Yang J; Young MJ
    J Hum Hypertens; 2021 Feb; 35(2):110-116. PubMed ID: 32467588
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The Met852 residue is a key organizer of the ligand-binding cavity of the human mineralocorticoid receptor.
    Fagart J; Seguin C; Pinon GM; Rafestin-Oblin ME
    Mol Pharmacol; 2005 May; 67(5):1714-22. PubMed ID: 15716462
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The synthetic androgen methyltrienolone (r1881) acts as a potent antagonist of the mineralocorticoid receptor.
    Takeda AN; Pinon GM; Bens M; Fagart J; Rafestin-Oblin ME; Vandewalle A
    Mol Pharmacol; 2007 Feb; 71(2):473-82. PubMed ID: 17105867
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Transactivation and synergistic properties of the mineralocorticoid receptor: relationship to the glucocorticoid receptor.
    Rupprecht R; Arriza JL; Spengler D; Reul JM; Evans RM; Holsboer F; Damm K
    Mol Endocrinol; 1993 Apr; 7(4):597-603. PubMed ID: 8388999
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The mineralocorticoid activity of progesterone derivatives depends on the nature of the C18 substituent.
    Souque A; Fagart J; Couette B; Davioud E; Sobrio F; Marquet A; Rafestin-Oblin ME
    Endocrinology; 1995 Dec; 136(12):5651-8. PubMed ID: 7588320
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Structural and biochemical mechanisms for the specificity of hormone binding and coactivator assembly by mineralocorticoid receptor.
    Li Y; Suino K; Daugherty J; Xu HE
    Mol Cell; 2005 Aug; 19(3):367-80. PubMed ID: 16061183
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Activating mineralocorticoid receptor mutation in hypertension exacerbated by pregnancy.
    Geller DS; Farhi A; Pinkerton N; Fradley M; Moritz M; Spitzer A; Meinke G; Tsai FT; Sigler PB; Lifton RP
    Science; 2000 Jul; 289(5476):119-23. PubMed ID: 10884226
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Homology model of dihydropyridine receptor: implications for L-type Ca(2+) channel modulation by agonists and antagonists.
    Zhorov BS; Folkman EV; Ananthanarayanan VS
    Arch Biochem Biophys; 2001 Sep; 393(1):22-41. PubMed ID: 11516158
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The mineralocorticoid receptor discriminates aldosterone from glucocorticoids independently of the 11 beta-hydroxysteroid dehydrogenase.
    Lombes M; Kenouch S; Souque A; Farman N; Rafestin-Oblin ME
    Endocrinology; 1994 Sep; 135(3):834-40. PubMed ID: 8070376
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Identification of ligand-selective peptide antagonists of the mineralocorticoid receptor using phage display.
    Yang J; Chang CY; Safi R; Morgan J; McDonnell DP; Fuller PJ; Clyne CD; Young MJ
    Mol Endocrinol; 2011 Jan; 25(1):32-43. PubMed ID: 21106883
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Characterization of the retinoid orphan-related receptor-alpha coactivator binding interface: a structural basis for ligand-independent transcription.
    Harris JM; Lau P; Chen SL; Muscat GE
    Mol Endocrinol; 2002 May; 16(5):998-1012. PubMed ID: 11981035
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Model structures of the N-methyl-D-aspartate receptor subunit NR1 explain the molecular recognition of agonist and antagonist ligands.
    Moretti L; Pentikäinen OT; Settimo L; Johnson MS
    J Struct Biol; 2004 Mar; 145(3):205-15. PubMed ID: 14960371
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The L-, N-, and T-type triple calcium channel blocker benidipine acts as an antagonist of mineralocorticoid receptor, a member of nuclear receptor family.
    Kosaka H; Hirayama K; Yoda N; Sasaki K; Kitayama T; Kusaka H; Matsubara M
    Eur J Pharmacol; 2010 Jun; 635(1-3):49-55. PubMed ID: 20307534
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Phosphorylation of Mineralocorticoid Receptor Ligand Binding Domain Impairs Receptor Activation and Has a Dominant Negative Effect over Non-phosphorylated Receptors.
    Jiménez-Canino R; Fernandes MX; Alvarez de la Rosa D
    J Biol Chem; 2016 Sep; 291(36):19068-78. PubMed ID: 27422824
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A conserved carboxy-terminal subdomain is important for ligand interpretation and transactivation by nuclear receptors.
    Lanz RB; Rusconi S
    Endocrinology; 1994 Nov; 135(5):2183-95. PubMed ID: 7956941
    [TBL] [Abstract][Full Text] [Related]  

  • 59. 19-Nor progesterone is a mineralocorticoid agonist.
    Funder JW; Adam WR
    Endocrinology; 1981 Jul; 109(1):313-5. PubMed ID: 6263590
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The evolution of mineralocorticoid receptors.
    Hu X; Funder JW
    Mol Endocrinol; 2006 Jul; 20(7):1471-8. PubMed ID: 16195247
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.